Search results
6 cze 2023 · Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world.
Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors. [17] [18] One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia. [19]
31 sty 2024 · Memantine is an uncompetitive, low-affinity, open-channel blocker that blocks the extrasynaptic NMDA receptor (NMDAR) that selectively enters the receptor-associated ion channel during its open state.
Memantine is used to treat the symptoms of Alzheimer's disease (AD; a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Memantine is in a class of medications called NMDA receptor antagonists.
2 mar 2007 · Memantine, an NMDA receptor antagonist has been found to be effective, both as monotherapy and in combination with donepezil, in the treatment of patients with moderate to severe stage AD.
Memantine is an NMDA receptor antagonist used to treat moderate to severe dementia in Alzheimer's. Brand Names. Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric. Generic Name. Memantine. DrugBank Accession Number. DB01043. Background.
